no planned advisory committee
Launching in .Q4 ahead of schedule.
In driver seat if there is any BO talk.
'Go it alone" can bring out much better return for the shareholders.
BP has to pay significant premium and has not much time left if to bid for ITMN.
UBS says the chance of approval being 100%. You don't see this kind of number too often in WS.
Ascend trial data fulfilled FDA requirement from 2 years ago.
However, It's all priced in already.
Early launching is bigger news than this, IMO.